Updated just now · Live
Stock analysis, price data, and AI-powered insights for Janux Therapeutics Inc (JANX).
Janux Therapeutics Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for JANX.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). JANX Stock Intelligence Report. [stoxpulse.com/stocks/janx]
Disclaimer: The information on this page about Janux Therapeutics Inc (JANX) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Janux Therapeutics Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Barclays Downgrades Janux Therapeutics to Underwei...
1d ago
Janux Therapeutics Doses First Participant In Phas...
5d ago
StoxPulse AI results for JANX: Pulse Score 53/100. Primary sentiment trends from 4 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$965.4M
P/E Ratio
—
EPS
$-0.39
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Barclays Downgrades Janux Therapeutics to Underweight, Lowers Price Target to $14
Janux Therapeutics Doses First Participant In Phase 1 Clinical Study Of JANX014 To Treat Metastatic Castration-Resistant Prostate Cancer
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
UBS Downgrades Janux Therapeutics to Neutral, Lowers Price Target to $15